The Clinical Features of Combined Central and Peripheral Demyelination

Study Overview
=================
Brief Summary
-----------------
The investigators conduct this study to clarify the clinical features and to evaluate the prevalence of anti-nodal/paranodal antibodies of patients with combined central and peripheral demyelination (CCPD) .

Detailed Description
-----------------
The investigators will review the clinical manifestation, laboratory test results, electrophysiological examination and neuroimaging findings of patients with CCPD. And we will detect antibodies to aquaporin 4(AQP4), myelin oligodendrocyte glycoprotein (MOG), neurofascin-155 (Nfasc155), neurofascin-186 (Nfasc186), and myelin-associated glycoprotein (MAG) in patients with CCPD.

Official Title
-----------------
The Clinical Features of Combined Central and Peripheral Demyelination

Conditions
-----------------
Combined Central and Peripheral Demyelination Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: T2 high-signal intensity lesions in the brain or spinal cord on MRI, or visual-evoked potentials(VEPs) abnormalities. conduction delay, conduction block, temporal dispersion or F-wave abnormalities, suggesting peripheral demyelinating neuropathy regarding nerve conduction studies (NCS). Exclusion Criteria: infectious diseases(e.g., human T lymphocyte trophic virus type1-associated myelopathy, syphilis, neuroborreliosis, HIV infection or progressive multifocal leukoencephalopathy) pre-existing inflammatory diseases (e.g., sarcoidosis, Behçet's disease, Sjögren's syndrome, vasculitis or other collagen diseases) mitochondrial disease metabolic/toxic diseases (e.g., vitamin deficiency, amyloidosis, chronic alcoholism, diabetes mellitus or subacute myelo-opticoneuropathy due to clioquinol intoxication cervical spondylotic myelopathy syringomyelia spinocerebellar degeneration multiple myeloma, other tumors inherited diseases (e.g., leucodystrophies) cerebrovascular disease non-specific lesions on T2-weighted MRI (e.g., leucoaraiosis).
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with CCPD<br>Inclusion criteria： Criteria for central nervous system involvement: T2 high-signal intensity lesions in the brain, or spinal cord on MRI, or visual-evoked potentials(VEPs) abnormalities. Criteria for peripheral nervous system involvement: conduction delay, conduction block, temporal dispersion or F-wave abnormalities, suggesting peripheral demyelinating neuropathy regarding nerve conduction studies (NCS). In the present study, it was compulsory for at least two nerves between the median, ulnar, tibial and peroneal nerves to have abnormal findings indicating demyelination. Exclusion criterion: Secondary demyelinating diseases or changes. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Laboratory findings of nodal/paranodal antibodies in blood of patients with CCPD | These antibody including anti-neurofascin 155(NF155) et.al. | Day 1 post-gathering information of patients in hospital medical record system | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Demographic characteristics | The demographic characteristics of patients with CCPD such as age,sex,and et.al | Day 1 post-gathering information of patients in hospital medical record system | 
| Neurological symptoms and signs | The neurological symptoms and signs of patients with CCPD | Day 1 post-gathering information of patients in hospital medical record system | 
| Laboratory findings of blood and cerebrospinal fluid | Laboratory findings of blood and cerebrospinal fluid of patients with CCPD such as C reactive protein et.al in blood and protein et.al in cerebrospinal fluid | Day 1 post-gathering information of patients in hospital medical record system | 
| Neuroimaging and VEPs findings | Neuroimaging and VEPs findings of patients with CCPD | Day 1 post-gathering information of patients in hospital medical record system | 
| Nerve conduction study findings | Nerve conduction study findings of patients with CCPD | Day 1 post-gathering information of patients in hospital medical record system | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
CCPD, clinical features, antibody